- Staff Changes Made In Concert with Corporate Reorganization -
WEST BRIDGEWATER, Mass., July 22 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) an infectious diseases management company, today announced that four senior staff members have been named as Senior Vice Presidents and General Managers of the Company's newly formed business units, each with direct revenue and profit responsibility. In addition, the Company also appointed six other employees to key positions. BBI's transition to a business unit structure and the related staff changes are directed toward utilizing resources most effectively to increase revenue and profitability within each business.
BBI Diagnostics
Barry M. Warren will become Senior Vice President and General Manager of the Company's BBI Diagnostics business unit, which is focused on manufacturing and selling quality control and other diagnostic products to increase the accuracy of in-vitro diagnostic tests for infectious diseases. BBI Diagnostics is currently being formed as a legal entity; previously, all quality control and other diagnostic products were sold under the parent company name, "Boston Biomedica, Inc." Since 1993, Mr. Warren has served as Senior Vice President, Sales and Marketing. Prior to that, he served as Group Director of Marketing of Organon Teknika, a manufacturer of infectious disease reagents and worked for several years at different positions with Abbott Laboratories.
BBI Clinical Laboratories
Patricia Garrett, Ph.D., will become Senior Vice President and General Manager of the Company's BBI Clinical Laboratories business unit, which is focused on providing specialty laboratory testing services for the infectious diseases industry. Since 1988, Dr. Garrett has served as BBI's Senior Vice President, Regulatory Affairs and Strategic Programs. Previously, she served as the Technical Director of the Chemistry Laboratory, Department of Laboratory Medicine, at the Lahey Clinic Medical Center. On a corporate level, Dr. Garrett will continue to be involved with several strategic programs, including being Principal Investigator on an HIV surveillance contract with the Centers for Disease Control (CDC).
BBI Biotech Research Laboratories
Mark M. Manak, Ph.D, will become Senior Vice President and General Manager of the Company's BBI Biotech Research Laboratories business unit, which is focused on providing research and development services for the other BBI business units as well as contract research services to the infectious disease industry. Since 1992, Dr. Manak has served as BBI's Senior Vice President, Research and Development. Prior to that, he served as Director of Contract and Services of Biotech Research Laboratories.
BBI Source Scientific
David Petersen will become Senior Vice President and General Manager of the Company's BBI Source Scientific business unit, which is focused on developing, manufacturing and marketing laboratory and diagnostic instruments for infectious disease testing. Mr. Petersen has over 22 years of experience in operations management and materials planning. Before joining BBI in 1998 as Vice President, Laboratory Instrumentation, he held key management positions for Matrix Instruments and Farr Company, Inc.
Each business unit's General Manager will report directly to Kevin Quinlan, BBI's newly appointed President and Chief Operating Officer. "These four individuals are ideally suited to play the critical role of leading each of our business units," commented Mr. Quinlan. "Each has extensive experience in his or her area of focus and a demonstrated track record of achievement. The foremost goal of our reorganization is to enable us to increase the profitability of each of our business units. I feel very confident to have these individuals at the helm."
BBI also announced new corporate positions for several other senior staff members as a result of the Company's reorganization. William R. Prather, M.D., currently Senior Vice President of Business Development, will become Senior Vice President of Finance and Business Development and will assume many of the financial responsibilities formerly filled by Kevin Quinlan as Chief Financial Officer. Richard C. Tilton, Ph.D., currently Senior Vice President of Laboratory Services at BBICL, will become Senior Vice President of Science and Technology for the parent Company. Graham Allaway Ph.D., currently Vice President of Drug Development will become Senior Vice President for Drug Development. Edward H. Myles CPA, currently Director of Finance at BBIDx, will become Corporate Controller and work closely with Dr. Prather. Linda St. Germain, currently Director of Marketing at BBIDx, will become Vice President, Sales and Marketing and Janet A. O'Connor, currently Director, QA/QC at BBI Diagnostics will become Director, QA/QC and Regulatory Affairs for BBIDx.
Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases such as HIV, Lyme Disease, Hepatitis, and other pathogens. The Company has four business units: (1) BBI Diagnostics, focused on manufacturing and selling quality control products to increase the accuracy of in-vitro diagnostic tests, (2) BBI Clinical Laboratories, focused on providing specialty laboratory testing services in infectious diseases, (3) BBI Biotech Research Laboratories, focused on providing R&D support for the other BBI business units as well as contract research services for third parties, and (4) BBI Source Scientific, focused on developing laboratory and diagnostic instruments. In addition, the Company is pursuing research and development programs in the areas of pressure cycling technology (PCT) and drug discovery, with the goal of introducing new solutions for the detection and treatment of infectious diseases.
Statements contained in this news release that state the Company's or
management's intentions, hopes, beliefs, expectations or predictions of the
future are "forward-looking" statements. It is important to note that the
Company's actual results could differ materially from those projected in such
forward-looking statements. Factors that could cause actual results to differ
from those projected include the possibility that due to unforeseen technical,
financial and other difficulties Boston Biomedica, Inc. may not be able to
develop its research and development programs into commercially successful
products, or such development may take longer than currently expected or that
the reorganization of the corporate structure & management may not lead to
increased profitability or R&D program acceleration. Additional information
concerning factors that could cause actual results to differ materially from
those in the forward-looking statements is contained from time to time in the
Company's SEC filings, including but not limited to the Company's report on
Form 10-Q for the period ended March 31, 1999. Copies of this document may be
obtained by contacting the Company or the SEC.
SOURCE Boston Biomedica, Inc.
Web site: http: //www.bbii.com
CONTACT: Richard T. Schumacher, Pres. & CEO, or Kevin W. Quinlan, CFO, or William R. Prather, M.D., Sr. VP Business Dvlp., all of Boston Biomedica, Inc., 508-580-1900
